Trial Profile
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Tenofovir
- Indications Hepatitis B; Liver cirrhosis
- Focus Therapeutic Use
- 23 Mar 2017 New trial record